Dual Marker Co-Expressed Exosome-Based Liquid Biopsy Electrochemical Assay for Enhanced-Accuracy Diagnosis of Prostate Cancer
ACS Sensors · 24.07.2026 · 11 (7) · 5462-5473
DOI: 10.1021/acssensors.5c04025 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Sensors, online erschienen am 08.07.2026. Verfasst von Feng Wei und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu221002, China. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Exosomes, Electrochemical Techniques, Biomarkers, Tumor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: Basic Research Program of Jiangsu Province, National Key Research and Development Program of China, Xuzhou Medical University.
Abstract (Originalsprache)
Tumor-derived exosomes (TDEs) have emerged as clinically significant liquid biopsies for noninvasive early cancer diagnosis. Although serum prostate-specific antigens (PSA) are widely used for prostate cancer (PCa) screening, their diagnostic accuracy is compromised by elevated levels in nonmalignant conditions. B7H3, a protein overexpressed on cancer cell membranes, shows promise as a tumor diagnostic marker but lacks PCa specificity. To address these limitations, we developed an analytical platform for high-accuracy PCa screening via the co-recognition of dual exosomal markers (PSA and B7H3) using a paper-based electrochemical immunosensor. Magnetic Fe3O4 nanoparticles functionalized with multivalent PSA aptamers captured PSA+ TDEs, while anti-B7H3-conjugated iron–manganese silicate nanozymes (IMSNs) amplified the electrochemical signals. A specific electrochemical response occurred only when both markers were highly expressed on TDEs, eliminating false positives from inflammation-induced PSA elevation. Coupled with high sensitivity (detection limit: 81 particles/mL) and specificity for TDEs detection, the assay successfully screened 50 PCa patients, 33 benign prostatic hyperplasia (BPH) patients, and 20 healthy controls, enabling enhanced-accuracy diagnosis of PCa.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu221002, China.
- Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, Jiangsu221004, China.
- School of Medical Technology, Xuzhou Medical University, Xuzhou, Jiangsu221004, China.
- Department of Nuclear Medicine Laboratory, Affiliated Hospital of Xuzhou Medical University, Xuzhou221002, China.
- Department of Laboratory Medicine, Huashan Hospital, Fudan University, Shanghai200032, China.
Förderung
- Basic Research Program of Jiangsu Province
- National Key Research and Development Program of China
- Xuzhou Medical University
Zitieren
APA
Wei, F., Jiang, Q., Chen, W., Chen, F., Zhang, M., Yu, Y., Guan, M., & Li, S. (2026). Dual Marker Co-Expressed Exosome-Based Liquid Biopsy Electrochemical Assay for Enhanced-Accuracy Diagnosis of Prostate Cancer. ACS Sensors, 11(7), 5462-5473. https://doi.org/10.1021/acssensors.5c04025
Vancouver
Wei F, Jiang Q, Chen W, Chen F, Zhang M, Yu Y, et al. Dual Marker Co-Expressed Exosome-Based Liquid Biopsy Electrochemical Assay for Enhanced-Accuracy Diagnosis of Prostate Cancer. ACS Sensors. 2026;11(7):5462-5473. doi:10.1021/acssensors.5c04025
BibTeX
@article{Wei2026,
author = {Wei, Feng and Jiang, Qingqing and Chen, Wenbai and Chen, Fang and Zhang, Miaomiao and Yu, Yanyan and Guan, Ming and Li, Shibao},
title = {Dual Marker Co-Expressed Exosome-Based Liquid Biopsy Electrochemical Assay for Enhanced-Accuracy Diagnosis of Prostate Cancer},
journal = {ACS Sensors},
year = {2026},
volume = {11},
number = {7},
pages = {5462--5473},
doi = {10.1021/acssensors.5c04025}
}
EUVIMED